An antibody–drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

被引：0
|
作者：
Joan Jacob
Liezl E. Francisco
Treena Chatterjee
Zhengdong Liang
Shraddha Subramanian
Qingyun J. Liu
Julie H. Rowe
Kendra S. Carmon
机构：
[1] University of Texas Health Science Center at Houston,Center for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine
[2] University of Texas Health Science Center at Houston,Department of Internal Medicine, McGovern Medical School
来源：
British Journal of Cancer | 2023年 / 128卷 / 8期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1592 / 1602
页数：10
相关论文
共 50 条
  • [1] An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
    Jacob, Joan
    Francisco, Liezl E.
    Chatterjee, Treena
    Liang, Zhengdong
    Subramanian, Shraddha
    Liu, Qingyun J.
    Rowe, Julie H.
    Carmon, Kendra S.
    BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1592 - 1602
  • [2] GPR56 as a therapeutic target for the development of antibody-drug conjugates for the treatment of colorectal cancer
    Francisco, Liezl E.
    Chatterjee, Treena
    Liang, Zhengdong
    Zhang, Sheng
    Carmon, Kendra
    CANCER RESEARCH, 2022, 82 (12)
  • [3] An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
    Sano, Renata
    Krytska, Kateryna
    Larmour, Colleen E.
    Raman, Pichai
    Martinez, Daniel
    Ligon, Gwenda F.
    Lillquist, Jay S.
    Cucchi, Ulisse
    Orsini, Paolo
    Rizzi, Simona
    Pawel, Bruce R.
    Alvarado, Diego
    Mosse, Yael P.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (483)
  • [4] Prognostic impact of GPR56 in patients with colorectal cancer
    Lim, Dae-Ro
    Kang, Dong-Hyun
    Kuk, Jung-Chul
    Kim, Tae-Hyung
    Shin, Eung-Jin
    Ahn, Tae-Sung
    Kim, Hyeong-Joo
    Jeong, Dong-Jun
    Baek, Moo-Jun
    Kim, Nam-Kyu
    NEOPLASMA, 2021, 68 (03) : 580 - 589
  • [5] An Antibody Drug Conjugate targeting HER-3 demonstrates promising antitumor efficacy in a wide range of human cancer
    Sala, Gianluca
    Iezzi, Manuela
    Lamolinara, Alessia
    Capone, Emily
    Iacobelli, Stefano
    Sauniere, Jean-Fred
    Ponziani, Sara
    Giansanti, Francesco
    Ippoliti, Rodolfo
    CANCER RESEARCH, 2017, 77
  • [6] Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET
    van Scheltinga, Anton G. T. Terwisscha
    Ogasawara, Annie
    Pacheco, Glenn
    Vanderbilt, Alexander N.
    Tinianow, Jeff N.
    Gupta, Nidhi
    Li, Dongwei
    Firestein, Ron
    Marik, Jan
    Scales, Suzie J.
    Williams, Simon-Peter
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (01) : 134 - 142
  • [7] A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma
    Sano, Renata
    Krytska, Kateryna
    Larmour, Colleen
    Ligon, Gwenda F.
    Lillquist, Jay S.
    Cucchi, Ulisse
    Orsini, Paolo
    Rizzi, Simona
    McMahon, Gerald
    Alvarado, Diego
    Mosse, Yael P.
    CANCER RESEARCH, 2016, 76
  • [8] Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers
    Wong, Po Yee
    He, Lin
    Chow, Kronos
    Wong, Kwan Wa
    O, Chui Yee
    Wong, Dennis
    Luk, John Moon
    Lo, Pui-Chi
    Wong, Kwong Fai
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Development and characterization of an epiregulin antibody-drug conjugate for targeting colorectal cancer cell plasticity
    Jacob, Joan
    Liang, Zhengdong
    Carmon, Kendra
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Preclinical development of a novel antibody-drug conjugate targeting "cold" tumors
    Kaplan, Angelo
    Attanasio, Nickolas
    Do, To Uyen T.
    Swaminathan, Sudha
    Bisht, Arnima
    Lou, San Lin
    Allen, Jason
    Boyd, Robert
    Ackroyd, James E.
    Feldman, Gleb
    Rohlff, Christian
    Dusek, Rachel L.
    CANCER RESEARCH, 2018, 78 (13)
12345